FDA Posts Briefing Documents for Advisory Committee Meeting to Review Kyndrisa™ (drisapersen) for the Potential Treatment of Duchenne Muscular Dystrophy Amendable to Exon 51 Skipping
Go back to FDA Posts Briefing Documents for Advisory Committee Meeting to Review Kyndrisa™ (drisapersen) for the Potential Treatment of Duchenne Muscular Dystrophy Amendable to Exon 51 Skipping| BioMarin Pharmaceuticals, Inc. (NASDAQ: BMRN) | Delayed: 63.94 -1.14 (1.75%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $65.08 | 52 Week High | $108.96 | |||
| Open | $65.25 | 52 Week Low | $62.12 | |||
| Day High | $65.29 | P/E | N/A | |||
| Day Low | $63.84 | EPS | $-1.27 | |||
| Volume | 4,455,960 | |||||
